Clinical characteristics of adults with T2DM before and after treatment with 30 mg/day pioglitazone (PIO) for >11 weeks (Cohort 2).

Subscripts refer to pre-intervention1 or post-intervention2 with pioglitazone (PIO)* pC/NC—Caucasian, non-Caucasian; FPG—fasting plasma glucose; TG—serum triglyceridesTotal body fat and lean masses measured by DEXAClinical characteristics of adults with T2DM before and after treatment with 30 mg/day pioglitazone (PIO) for >11 weeks (Cohort 2).下标1代表干预前状态，下标2代表接受吡格列酮（pioglitazone, PIO）*干预后的状态。其中：pC/NC指高加索人群、非高加索人群；FPG为空腹血浆葡萄糖（fasting plasma glucose）；TG为血清甘油三酯；体脂总量与去脂体重通过双能X线吸收法（DEXA）测定。本数据集收录了每日口服30mg吡格列酮（PIO）且治疗周期超过11周的2型糖尿病（Type 2 Diabetes Mellitus, T2DM）成人患者的治疗前后临床特征（队列2）。